Ad is loading...
CFVLX
Price
$35.96
Change
+$0.35 (+0.98%)
Updated
Nov 22 closing price
VVIAX
Price
$69.72
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

CFVLX vs VVIAX

Header iconCFVLX vs VVIAX Comparison
Open Charts CFVLX vs VVIAXBanner chart's image
Commerce Value
Price$35.96
Change+$0.35 (+0.98%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index Adm
Price$69.72
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
CFVLX vs VVIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CFVLX vs. VVIAX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CFVLX is a Buy and VVIAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 184B vs. CFVLX (279M). CFVLX (2.37) and VVIAX (2.36) have matching dividends . CFVLX was incepted earlier than VVIAX: CFVLX (28 years) vs VVIAX (24 years). CFVLX is a more actively managed with annual turnover of: 46.00 vs. VVIAX (10.00). CFVLX has a lower initial minimum investment than VVIAX: CFVLX (1000) vs VVIAX (3000). VVIAX annual gain was more profitable for investors over the last year : 26.09 vs. CFVLX (20.10). VVIAX return over 5 years is better than : 53.09 vs. CFVLX (22.78).
CFVLXVVIAXCFVLX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence28 years24 years-
Gain YTD16.21919.67282%
Front LoadN/AN/A-
Min. Initial Investment1000300033%
Min. Initial Investment IRAN/AN/A-
Net Assets279M184B0%
Annual Yield % from dividends2.372.36101%
Returns for 1 year20.1026.0977%
Returns for 3 years5.7324.7723%
Returns for 5 years22.7853.0943%
Returns for 10 years32.15112.2629%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOLE15.260.19
+1.26%
Dole plc
NCNO40.450.37
+0.92%
nCino
SGHT3.760.03
+0.80%
Sight Sciences
VICI32.370.25
+0.78%
VICI Properties
SABS3.070.01
+0.33%
SAB Biotherapeutics